Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending ...

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

ReBoost Nasal Spray was recalled after it was "found to contain yeast/mold and microbial contamination," the FDA states, adding, "There is a reasonable probability that adverse health consequences, ...

Profs Carl Philpott and Claire Hopkins discuss how the MACRO trial challenges long-held assumptions about chronic ...

A nasal spray that was distributed across the United States has been recalled due to its potential to cause 'life-threatening ...

Angela Read thought she had a sinus infection, soon she discovered her condition was much more serious. She's grateful to the ...

Cystic fibrosis, a genetic disorder, affects lungs and other organs. It causes thick mucus buildup. Researchers have ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines ...